New Advances in Skin Cancer Detection
New biomarkers to improve skin cancer detection and avoid delays in treatment are being developed by researchers in Australia.
New biomarkers to improve skin cancer detection and avoid delays in treatment are being developed by researchers in Australia.
Thermo Fisher Scientific is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic test for Tagrisso.
Micronoma announced its OncobiotaLUNG assay received the Breakthrough Device Designation from the U.S. FDA for lung carcinoma detection.
The FDA granted Datar Cancer Genetics Breakthrough Device Designation for its TriNetra-Glio test, a liquid biopsy to diagnose brain tumors.
Read MoreBurning Rock announced that its OverC Multi-Cancer Detection Blood Test has been granted Breakthrough Device Designation by the FDA.
Read MoreGuardant Health unveiled results from a 20,000 patient study evaluating the performance of its blood test for detecting colorectal cancer.
Read MoreAlercell is launching a leukemia diagnostic test based on sequencing DNA that will detect up to 51 Genes mutations in Leukemia patients.
Read MoreResearchers are revealing connections between cancer and race or ethnicity with software that infers ancestral roots in tumor DNA and RNA.
Read MoreResearchers have made an advancement in genetic testing that allows for more accurate prediction of individual’s increased cancer risk.
Read MoreAn analysis of more than 100,000 colorectal cancer cases uncovered hundreds of signals that may serve as new prevention targets.
Read MoreBluestar Genomics has announced its U.S. and international commercialization of a test for early detection of pancreatic cancer.
Read MoreThe Children’s Tumor Foundation will conduct a study to see if DNA-based blood tests offer a better understanding of cancer in NF1 patients.
Read MoreThe new findings could help clinicians better determine who’s at the highest risk for colorectal cancer so they can receive early screening.
Read MoreResearchers devised a new biomarker-based strategy to screen for a deadly complication caused by monoclonal antibodies used to treat cancer.
Read MoreResearchers pioneered and implemented a novel algorithm to provide genetic testing to patients with newly diagnosed prostate cancer.
Read MoreIbex Medical Analytics announced the live deployment by the University of Pittsburgh Medical Center (UPMC) of Galen Prostate.
Read MoreAgilent Technologies announced that the FDA has approved the ctDx FIRST as a companion diagnostic to identify advanced NSCLC.
Read MoreCambridge scientists have created a comprehensive tool for predicting an individual’s risk of developing prostate cancer.
Read More